Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

NCT02880371 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02880371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02880371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
September 1, 2016
Completion date
October 24, 2019
Enrollment
82 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors